Clearpoint Stock Story

CLPT -  USA Stock  

USD 12.24  0.79  6.06%

It looks like Bio-Rad Laboratories will continue to recover much faster as its share price surged up 0.19% today to Clearpoint Neuro's 6.8412%. While some of us are excited about healthcare space, we will evaluate how stable are Clearpoint Neuro and Bio-Rad Laboratories fundamentals. We are going to break down some of the competitive aspects of both Clearpoint and Bio-Rad.
Published over a month ago
View all stories for Clearpoint Neuro | View All Stories
Our viewpoint on Clearpoint Neuro (NYSEMKT:CLPT) and Bio Rad Laboratories (NYSE:BIO)?
By analyzing existing basic indicators between Clearpoint Neuro and Bio-Rad, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Bio-Rad with a short position in Clearpoint Neuro. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Clearpoint Neuro has an asset utilization ratio of 150.66 percent. This implies that the company is making $1.51 for each dollar of assets. An increasing asset utilization means that Clearpoint Neuro is more efficient with each dollar of assets it utilizes for everyday operations.

How important is Clearpoint Neuro's Liquidity

Clearpoint Neuro financial leverage refers to using borrowed capital as a funding source to finance Clearpoint Neuro ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Clearpoint Neuro financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Clearpoint Neuro's total debt and its cash.

How Clearpoint utilizes its cash?

To perform a cash flow analysis of Clearpoint Neuro, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Clearpoint Neuro is receiving and how much cash it distributes out in a given period. The Clearpoint Neuro cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Clearpoint Neuro Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Clearpoint Neuro reported Net Cash Flow from Operations of (7.81 Million) in 2020

Going after Clearpoint Financials

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me take a closer look at Clearpoint Neuro revenue. Based on the latest financial disclosure, Clearpoint Neuro reported 14.68 M of revenue. This is 99.81% lower than that of the Healthcare sector and 99.42% lower than that of the Medical Devices industry. The revenue for all United States stocks is 99.84% higher than that of Clearpoint Neuro. As for Bio-Rad Laboratories we see revenue of 2.88 B, which is 12.91% higher than that of the Medical Devices

Sector
2.6 B
BIO
2.9 B
CLPT14.68 Million0.27
Sector2.55 Billion46.84
BIO2.88 Billion52.89

Our perspective of the newest Clearpoint Neuro gain

Newest Sortino Ratio is up to 0.04. Price may drop again. Clearpoint Neuro exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Clearpoint Neuro individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Clearpoint Neuro future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Clearpoint Neuro's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Clearpoint Neuro's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Clearpoint Neuro

Whereas few other entities within the medical devices industry are still a little expensive, even after the recent corrections, Clearpoint Neuro may offer a potential longer-term growth to private investors. To summarize, as of the 16th of October 2021, our ongoing 90 days 'Buy-vs-Sell' recommendation on the firm is Hold. We believe Clearpoint Neuro is undervalued with very high probability of bankruptcy for the next two years.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Clearpoint Neuro. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com